Human FGF-19 Antibody

Detection of Human FGF‑19 by Western Blot. Western blot shows lysates of COLO 205 human colorectal adenocarcinoma cell line, conditioned media from COLO 205 cell line, and HT-29 human colon adenocarcinoma cell line. PVDF membrane was probed with 0.5 µg/mL of Goat Anti-Human FGF-19 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF969) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for FGF-19 at approximately 22 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

Detection of Human FGF‑19 by Simple Western^TM. Simple Western lane view shows conditioned media from COLO 205 human colorectal adenocarcinoma cell line and HT-29 human colon adenocarcinoma cell line, loaded at 0.2 mg/mL. A specific band was detected for FGF-19 at approximately 26 kDa (as indicated) using 10 µg/mL of Goat Anti-Human FGF-19 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF969) followed by 1:50 dilution of HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). This experiment was conducted under reducing conditions and using the 2-40 kDa separation system.

Detection of FGF-19 by Western Blot Overexpression of FGF19 promotes the proliferation of LSQ cells in vitro and in vivo.SK-MES-1 and HCC95 cells were transduced with FGF19 overexpression lentivirus (FGF19-OE), or control lentivirus (FGF19-EV) to construct stable cell lines. a Quantification of the overexpression of FGF19 in forms as cellular protein (a), mRNA (b) or secreted protein in conditioned medium (c) in SK-MES-1 cells. b Enrichment plots of PCNA expression signatures according to FGF19 expression levels in an LSQ cohort. c Cell proliferation assays of the SK-MES-1 and HCC95 stable cells with FGF19 overexpression. d Colony formation in SK-MES-1 cells with or without FGF19 overexpression. e The effect of overexpression of FGF19 on the apoptosis induced by cisplatin in HCC95 cell lines. f Enrichment plots of cell cycle signatures according to FGF19 expression levels in an LSQ cohort. g Images of tumor nodules from subcutaneous mouse xenograft model with or without FGF19 overexpression. h (a) Western blot analysis of FGF19 and PCNA expression in tumors; (b) serum samples of FGF19 expression; (c) volume of tumors; and (d) body weight of mice from the two groups. i IHC analysis of Ki-67 expression in tumors. j Oil red O analysis of tumors from the two groups. Data are represented as mean and SEM from three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/32111983), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of FGF-19 by Western Blot FGF19 enhances CCND1-induced inactivation of RB. (A) rhFGF19 phosphorylated RB and promoted expression of CCND1 in SK-MES-1 and H520 cells in a time-dependent manner. (B) pRB and CCND1levels in FGF19 overexpression (SK-MES-1 LV-FGF19) and control (LV-NC) LUSC cells. (C) SK-MES-1 LV-FGF19 cells was transduced with CCND1-knockdown lentivirus (LV-shCCND1), or control lentivirus (LV-shRNA-NC) to construct stable cell lines and quantification of CCND1 in forms as cellular protein and mRNA. (D) pRB and CCND1 levels in FGF19 overexpression and CCND1-knockdown cells (SK-MES-1 LV-FGF19-shCCND1) and control (SK-MES-1 LV-NC-shRNA-NC) LUSC cells. (E) pRB and CCND1 levels in CCND1 knockdown cells (H520-shCCND1) and control (H520-shRNA-NC) LUSC cells. (F) pRB levels in FGF19-knockdown cells (H520-shFGF19) and control (H520-shRNA-NC) LUSC cells, treated with BLU9931, palbociclib, BLU9931 & palbociclib, or DMSO. Right panel: quantifications of pRB. All the data were shown as the mean ± SD. *P <0.05; **P <0.01; ***p <0.001; ****p <0.0001; ns, not significant. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35463335), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of FGF-19 by Western Blot CDCA and ER stress induce FGF19 upregulation and hFGF19 activates ERK/AKT signaling to promote LSQ cell proliferation. A FGF19 (a) and FGFR4 (b) mRNA expression levels in LSQ cell lines and Beas-2b. b Protein expression levels of FGF19 and FGFR4 in LSQ cell lines and bronchial epithelial cell line Beas-2b. c The effects of chenodeoxycholic acid (CDCA) treatment on FGF19 protein levels in Beas-2b cells in a dose-dependent (ranging from 0 to 100 µM, upper panel) and time-dependent (within 48 h, lower panel) manner. d The effect of chenodeoxycholic acid treatment (50 µM) on the apoptosis of Beas-2b cells with quantifications of the results on the right panel. e mRNA expression of FGF19 (left panel) and GRP78 (right panel) of LSQ cell lines H520 and SK-MES-1 treated with thapsigargin (TG) or tunicamycin (TM) for 24 h. f FGF19 protein expression of H520 and SK-MES-1 treated with TG or TM for 24 h, in the presence or absence of ER stress suppressor silymarin. g Cell proliferation of SK-MES-1 cells treated with conditioned medium from H520 cells overexpressing FGF19 was determined by CCK-8 assays. h The effects of hFGF19 on the activation of ERK/AKT signaling in SK-MES-1 cells in a dose-dependent (left panel) or time-dependent (right panel) manner. i Enrichment plots of mTOR expression signatures according to FGF19 expression levels in an LSQ cohort. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/32111983), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of FGF-19 by Western Blot CCND1 is essential for FGF19 signaling-mediated LUSC proliferation. (A) Western blot analysis showing protein levels of FGF19 and PCNA in SK-MES-1, H520 and H1703 cells after lentivirus transfection. (B) Clone formation assay of SK-MES-1 cells with or without FGF19 overexpression. (C) Cell proliferation was measured by CCK8 assay in SK-MES-1 LV-FGF19 cells with or without CCND1 knockdown. (D) Clone formation assay of SK-MES-1 LV-FGF19 cells with or without CCND1 knockdown; cultures were stained with crystal violet. (E–J) Data of orthotopic lung cancer model. Cell suspension of SK-MES-1 LV-NC/LV-FGF19/LV-FGF19-shRNA-NC/LV-FGF19-shCCND1 (2 × 106 cells) in a total volume of 50 μL mixed with Matrigel (Matrigel: PBS = 1: 4) were injected into the left lung of 5-week-old male BALB/C nude mice (N = 13 mice per group). (E) Experimental timeline for the animal experiment. (F) Representative bioluminescent images (BLI) of the different groups are shown 25 days after orthotopic implantation. Right panel: quantifications of the total flux. (G) Comparison of orthotopic lung cancer models. Tumor was indicated by the arrow. (H) Representative H&E and PCNA staining images of lung samples from each group. (I) Body weight change and (J) overall survival time of indicated groups of nude mice were showed. (K) Higher FGF19 and lower CCND1 mRNA levels are associated with longer overall survival. Data were showed as the mean ± SD. *p <0.05; **p <0.01; ***p <0.001; ****p <0.0001. H&E, hematoxylin and eosin. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35463335), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of FGF-19 by Western Blot FGF19 enhances CCND1-induced inactivation of RB. (A) rhFGF19 phosphorylated RB and promoted expression of CCND1 in SK-MES-1 and H520 cells in a time-dependent manner. (B) pRB and CCND1levels in FGF19 overexpression (SK-MES-1 LV-FGF19) and control (LV-NC) LUSC cells. (C) SK-MES-1 LV-FGF19 cells was transduced with CCND1-knockdown lentivirus (LV-shCCND1), or control lentivirus (LV-shRNA-NC) to construct stable cell lines and quantification of CCND1 in forms as cellular protein and mRNA. (D) pRB and CCND1 levels in FGF19 overexpression and CCND1-knockdown cells (SK-MES-1 LV-FGF19-shCCND1) and control (SK-MES-1 LV-NC-shRNA-NC) LUSC cells. (E) pRB and CCND1 levels in CCND1 knockdown cells (H520-shCCND1) and control (H520-shRNA-NC) LUSC cells. (F) pRB levels in FGF19-knockdown cells (H520-shFGF19) and control (H520-shRNA-NC) LUSC cells, treated with BLU9931, palbociclib, BLU9931 & palbociclib, or DMSO. Right panel: quantifications of pRB. All the data were shown as the mean ± SD. *P <0.05; **P <0.01; ***p <0.001; ****p <0.0001; ns, not significant. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35463335), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of FGF-19 by Western Blot CDCA and ER stress induce FGF19 upregulation and hFGF19 activates ERK/AKT signaling to promote LSQ cell proliferation. A FGF19 (a) and FGFR4 (b) mRNA expression levels in LSQ cell lines and Beas-2b. b Protein expression levels of FGF19 and FGFR4 in LSQ cell lines and bronchial epithelial cell line Beas-2b. c The effects of chenodeoxycholic acid (CDCA) treatment on FGF19 protein levels in Beas-2b cells in a dose-dependent (ranging from 0 to 100 µM, upper panel) and time-dependent (within 48 h, lower panel) manner. d The effect of chenodeoxycholic acid treatment (50 µM) on the apoptosis of Beas-2b cells with quantifications of the results on the right panel. e mRNA expression of FGF19 (left panel) and GRP78 (right panel) of LSQ cell lines H520 and SK-MES-1 treated with thapsigargin (TG) or tunicamycin (TM) for 24 h. f FGF19 protein expression of H520 and SK-MES-1 treated with TG or TM for 24 h, in the presence or absence of ER stress suppressor silymarin. g Cell proliferation of SK-MES-1 cells treated with conditioned medium from H520 cells overexpressing FGF19 was determined by CCK-8 assays. h The effects of hFGF19 on the activation of ERK/AKT signaling in SK-MES-1 cells in a dose-dependent (left panel) or time-dependent (right panel) manner. i Enrichment plots of mTOR expression signatures according to FGF19 expression levels in an LSQ cohort. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/32111983), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of FGF-19 by Western Blot FGF19 enhances CCND1 expression by FGF19-FGFR4-ERK1/2 axis in LUSC cells. (A) Recombinant human FGF19 (rhFGF19) (25 ng/ml) promoted expression of CCND1 in SK-MES-1 and H520 cells (serum starved for 12 h before treatment) in a time-dependent manner. (B) CCND1 mRNA expression levels in LUSC cell lines after treatment with rhFGF2 for 12 h. (C) Expression of CCND1 in FGF19 overexpression LUSC cell line. (D) Expression of CCND1 in FGF19 knockdown LUSC cell line. (E) A panel of inhibitors against a number of signaling pathways was used to dissect the leading factors of regulated by FGF19. (F) Western blot and (G) qPCR analysis of CCND1 expression in H520 and HCC95 LUSC cells after treatment of FGF19, FGF19 and SCH772984, FGF19 & BLU9931, or DMSO as control. (H) Effects of the FGF19/FGFR4 pathway on protein levels of CCND1, p-FGFR4, and p-ERK1/2 by western blot analysis. H520, SK-MES-1 and HCC95 cells were treated with FGF19 (25 ng/ml, 0/0.5/6/12 h) to activate the FGF19/FGFR4 signaling pathway. Data were shown as mean ± SD bars and compared by unpaired t-test. **p <0.01; ****p <0.0001; ns, not significant. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35463335), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of FGF-19 by Western Blot CDCA and ER stress induce FGF19 upregulation and hFGF19 activates ERK/AKT signaling to promote LSQ cell proliferation. A FGF19 (a) and FGFR4 (b) mRNA expression levels in LSQ cell lines and Beas-2b. b Protein expression levels of FGF19 and FGFR4 in LSQ cell lines and bronchial epithelial cell line Beas-2b. c The effects of chenodeoxycholic acid (CDCA) treatment on FGF19 protein levels in Beas-2b cells in a dose-dependent (ranging from 0 to 100 µM, upper panel) and time-dependent (within 48 h, lower panel) manner. d The effect of chenodeoxycholic acid treatment (50 µM) on the apoptosis of Beas-2b cells with quantifications of the results on the right panel. e mRNA expression of FGF19 (left panel) and GRP78 (right panel) of LSQ cell lines H520 and SK-MES-1 treated with thapsigargin (TG) or tunicamycin (TM) for 24 h. f FGF19 protein expression of H520 and SK-MES-1 treated with TG or TM for 24 h, in the presence or absence of ER stress suppressor silymarin. g Cell proliferation of SK-MES-1 cells treated with conditioned medium from H520 cells overexpressing FGF19 was determined by CCK-8 assays. h The effects of hFGF19 on the activation of ERK/AKT signaling in SK-MES-1 cells in a dose-dependent (left panel) or time-dependent (right panel) manner. i Enrichment plots of mTOR expression signatures according to FGF19 expression levels in an LSQ cohort. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/32111983), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of FGF-19 by Western Blot Overexpression of FGF19 promotes the proliferation of LSQ cells in vitro and in vivo.SK-MES-1 and HCC95 cells were transduced with FGF19 overexpression lentivirus (FGF19-OE), or control lentivirus (FGF19-EV) to construct stable cell lines. a Quantification of the overexpression of FGF19 in forms as cellular protein (a), mRNA (b) or secreted protein in conditioned medium (c) in SK-MES-1 cells. b Enrichment plots of PCNA expression signatures according to FGF19 expression levels in an LSQ cohort. c Cell proliferation assays of the SK-MES-1 and HCC95 stable cells with FGF19 overexpression. d Colony formation in SK-MES-1 cells with or without FGF19 overexpression. e The effect of overexpression of FGF19 on the apoptosis induced by cisplatin in HCC95 cell lines. f Enrichment plots of cell cycle signatures according to FGF19 expression levels in an LSQ cohort. g Images of tumor nodules from subcutaneous mouse xenograft model with or without FGF19 overexpression. h (a) Western blot analysis of FGF19 and PCNA expression in tumors; (b) serum samples of FGF19 expression; (c) volume of tumors; and (d) body weight of mice from the two groups. i IHC analysis of Ki-67 expression in tumors. j Oil red O analysis of tumors from the two groups. Data are represented as mean and SEM from three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/32111983), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of FGF-19 by Western Blot FGF19 enhances CCND1-induced inactivation of RB. (A) rhFGF19 phosphorylated RB and promoted expression of CCND1 in SK-MES-1 and H520 cells in a time-dependent manner. (B) pRB and CCND1levels in FGF19 overexpression (SK-MES-1 LV-FGF19) and control (LV-NC) LUSC cells. (C) SK-MES-1 LV-FGF19 cells was transduced with CCND1-knockdown lentivirus (LV-shCCND1), or control lentivirus (LV-shRNA-NC) to construct stable cell lines and quantification of CCND1 in forms as cellular protein and mRNA. (D) pRB and CCND1 levels in FGF19 overexpression and CCND1-knockdown cells (SK-MES-1 LV-FGF19-shCCND1) and control (SK-MES-1 LV-NC-shRNA-NC) LUSC cells. (E) pRB and CCND1 levels in CCND1 knockdown cells (H520-shCCND1) and control (H520-shRNA-NC) LUSC cells. (F) pRB levels in FGF19-knockdown cells (H520-shFGF19) and control (H520-shRNA-NC) LUSC cells, treated with BLU9931, palbociclib, BLU9931 & palbociclib, or DMSO. Right panel: quantifications of pRB. All the data were shown as the mean ± SD. *P <0.05; **P <0.01; ***p <0.001; ****p <0.0001; ns, not significant. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35463335), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of FGF-19 by Western Blot FGF19 enhances CCND1 expression by FGF19-FGFR4-ERK1/2 axis in LUSC cells. (A) Recombinant human FGF19 (rhFGF19) (25 ng/ml) promoted expression of CCND1 in SK-MES-1 and H520 cells (serum starved for 12 h before treatment) in a time-dependent manner. (B) CCND1 mRNA expression levels in LUSC cell lines after treatment with rhFGF2 for 12 h. (C) Expression of CCND1 in FGF19 overexpression LUSC cell line. (D) Expression of CCND1 in FGF19 knockdown LUSC cell line. (E) A panel of inhibitors against a number of signaling pathways was used to dissect the leading factors of regulated by FGF19. (F) Western blot and (G) qPCR analysis of CCND1 expression in H520 and HCC95 LUSC cells after treatment of FGF19, FGF19 and SCH772984, FGF19 & BLU9931, or DMSO as control. (H) Effects of the FGF19/FGFR4 pathway on protein levels of CCND1, p-FGFR4, and p-ERK1/2 by western blot analysis. H520, SK-MES-1 and HCC95 cells were treated with FGF19 (25 ng/ml, 0/0.5/6/12 h) to activate the FGF19/FGFR4 signaling pathway. Data were shown as mean ± SD bars and compared by unpaired t-test. **p <0.01; ****p <0.0001; ns, not significant. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35463335), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of FGF-19 by Western Blot Overexpression of FGF19 promotes metastasis of LSQ cells in vitro and in vivo. A Protein and b mRNA expression of EMT markers in the cells treated with FGF19-EV or FGF19-OE for 48 h in SK-MES-1 cells. c Analysis of correlation between CDH2 and FGF19 from Oncomine TCGA datasets. The images of migration abilities in FGF19-OE transfected cells in trans-well (d) and wound healing (e) assays, respectively. f Overexpression of FGF19 increased tumor growth in vivo in orthotopic lung cancer models. Representative image of primary tumors in the left lungs of orthotropic models on day 21 from each group after implantation of SK-MES-1 cells transfected with FGF19-OE and FGF19-EV. g Metastatic tumors in other organs. h Representative images of IHC analysis of Ki-67 expression in lung and tumors. Right panel: Quantification of Ki-67 expression. i (a) Evaluation of FGF19 expression in serum samples from two groups. (b) Mean primary tumor body weight and (c) survival curve for the mice in each treatment group evaluated. j Within the 57 NSCLC patients’ group, the serum levels of FGF19 in patients with metastasis (n = 34) were shown side by side with those of patients without metastasis (n = 23). Data are represented as mean and SEM from three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/32111983), licensed under a CC-BY license. Not internally tested by R&D Systems.